Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Price Target at $6.14

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have received a consensus recommendation of “Hold” from the nine research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $6.75.

A number of analysts have recently commented on the company. Wall Street Zen upgraded Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, May 31st. Guggenheim increased their price objective on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, April 10th. Rodman & Renshaw initiated coverage on Zentalis Pharmaceuticals in a research report on Thursday. They issued a “buy” rating and a $11.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Monday, July 6th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC lifted its position in Zentalis Pharmaceuticals by 177.6% during the 1st quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock worth $985,000 after buying an additional 396,233 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Zentalis Pharmaceuticals by 220.6% in the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after acquiring an additional 2,111,951 shares in the last quarter. Qube Research & Technologies Ltd acquired a new stake in shares of Zentalis Pharmaceuticals in the second quarter valued at about $37,000. Sei Investments Co. increased its position in shares of Zentalis Pharmaceuticals by 373.1% in the second quarter. Sei Investments Co. now owns 167,100 shares of the company’s stock valued at $194,000 after acquiring an additional 131,780 shares during the last quarter. Finally, Jane Street Group LLC raised its holdings in Zentalis Pharmaceuticals by 346.3% during the second quarter. Jane Street Group LLC now owns 664,061 shares of the company’s stock worth $770,000 after acquiring an additional 515,257 shares in the last quarter.

Zentalis Pharmaceuticals Stock Down 2.7%

Shares of ZNTL stock opened at $4.33 on Wednesday. Zentalis Pharmaceuticals has a 12-month low of $1.21 and a 12-month high of $6.95. The firm has a fifty day moving average of $4.15 and a 200-day moving average of $3.47. The company has a market capitalization of $308.25 million, a price-to-earnings ratio of -2.50 and a beta of 1.92.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.01). On average, equities analysts expect that Zentalis Pharmaceuticals will post -1.83 EPS for the current year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.